Breaking AI & Tech News Analyzed

The Discovery of PFAS in the Solent Strait Scientists have found high levels of toxic PFAS, or “forever chemicals”, in soil, water and throughout the marine food chain in the UK’s Solent strait, including at protected environmental sites, according to a new study. Extent of the Pollution In some samples, pollution was 13 times the safe threshold for coastal waters. Others, which were below legal limits for individual chemicals, failed tests for combined toxicity. The samples were taken from the Solent strait, which runs between the Isle of Wight and the mainland, forming part of the Channel. Sources of the Chemicals The chemicals are thought to have entered the environment from wastewater treatment plants, sewage outflows, historic landfills and nearby military sites. Researchers analysed government data, testing at water utilities, and their own samples from a dozen species of fish, seaweed and invertebrates. Impact on the Environment They found PFAS were entering the Solent in treated effluent from wastewater plants in Portsmouth and Fareham operated by Southern Water, the utility that provides drinking water and sewerage for Kent, Sussex, Hampshire and the Isle of Wight. The study also mapped 194 combined sewer overflow outfalls and more than 500 nearby historic landfills that researchers believe could also contribute to the pollution. Calls for Action Researchers said their findings highlighted the need to monitor chemicals in combination and to make a blanket ban on PFAS part of the government’s water reform agenda. Prof Alex Ford, a biologist at the University of Portsmouth and one of the study’s authors, said: “If there was an oil spill in the Solent that industry would have to pay for the restoration of those habitats, but that doesn’t happen with sewage.” Future Outlook The EU is moving towards a blanket PFAS ban, probably with some exceptions for medicine and other critical uses. The British government said it would consult on setting limits for the chemicals and carry out further tests when its own PFAS plan was published in February, promising a “framework … to understand where these chemicals are coming from, how they spread and how to reduce public and environmental exposure”.

The Global Initiative to Reproductive HealthIn a landmark development for women's healthcare, an unprecedented global collaborative effort has resulted in the official renaming of Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This significant shift in medical terminology aims to address long-standing concerns about the condition's name and bring fresh hope to the millions of women affected worldwide.The Evolution of PCOS TerminologyThe term 'Polycystic Ovarian Syndrome' has been used for decades to describe this common endocrine disorder affecting women of reproductive age. However, medical professionals and patient advocates have increasingly highlighted limitations in the current name, which focuses primarily on ovarian cysts while overlooking the broader metabolic and endocrine aspects of the condition.The new name, 'Polyendocrine Metabolic Ovarian Syndrome,' more accurately reflects the complex, systemic nature of the disorder, which involves multiple hormonal systems and metabolic processes beyond just ovarian characteristics.Understanding the Scope of PCOS ImpactPCOS/PMOS affects an estimated one in ten women of reproductive age globally, making it one of the most common endocrine disorders. The condition is associated with a range of symptoms including irregular menstrual cycles, hormonal imbalances, insulin resistance, and metabolic issues, which can significantly impact quality of life and long-term health outcomes.The renaming initiative represents a significant step forward in recognizing the complexity of this condition and improving both medical understanding and patient experiences.Shifting Medical Perceptions Through NamingThe terminology shift is expected to have profound implications for how healthcare providers approach diagnosis, treatment, and patient education. By emphasizing the metabolic and endocrine components of the condition, the new name encourages a more holistic approach to care that addresses the full spectrum of symptoms and health implications.For patients, the change represents validation of their experiences beyond reproductive concerns and recognition of the condition's systemic impact on overall health and wellbeing.The Future of Women's Metabolic HealthAs medical communities worldwide adopt the new terminology, researchers anticipate increased funding and focus on understanding the metabolic aspects of PMOS, potentially leading to more targeted treatments and improved outcomes for patients.This renaming effort underscores the importance of patient-centered approaches in medical terminology and sets a precedent for how conditions affecting women's health are described and understood in the future.

Scientists have unveiled a new giant sauropod from Thailand, naming it Nagatitan chaiyaphumensis. The discovery, detailed in Scientific Reports, positions the species as the largest known dinosaur from Southeast Asia and offers fresh clues about the region’s prehistoric environment.Discovery of Nagatitan chaiyaphumensis in Northeast ThailandThe fossil remains were first spotted by local residents a decade ago in the Chaiyaphum province, but systematic excavation only concluded in 2024. The specimen, recovered from one of the youngest Thai rock formations, displayed unique skeletal features that warranted classification as a new species within the sauropod lineage.Size and Weight Estimates Put Nagatitan Among the Largest SauropodsMeasurements indicate the herbivore stretched 27 metres (89 feet) long and weighed about 27 tonnes, comparable to the mass of nine adult elephants. Researchers note it likely outweighed the famous Diplodocus cast “Dippy” at the Natural History Museum by at least 10 tonnes. The animal is dated to have roamed the area between 100 and 120 million years ago, during the mid‑Cretaceous.Implications for Southeast Asian Paleontology and Regional HeritageAs the biggest dinosaur ever found in Southeast Asia, Nagatitan expands the known geographic range of late‑surviving sauropods, which were thought to have largely disappeared from the region when it became a shallow sea in the Cretaceous. The find underscores Thailand’s growing importance as a paleontological hotspot and adds to the modest list of 14 named Thai dinosaurs.Future Research Directions and Tourist OpportunitiesLead author Thitiwoot Sethapanichsakul—a University College London PhD student—suggests further fieldwork could clarify the dinosaur’s feeding habits, which likely involved bulk browsing of conifers and seed ferns. A life‑size reconstruction now stands at Bangkok’s Thainosaur Museum, hinting at increased scientific tourism and educational outreach in the region.

The AI Startup Valuation ShiftAnthropic has usurped OpenAI as the world's most valuable artificial intelligence startup, soaring to a $965bn valuation ahead of expected public listings by the rival firms. Anthropic, the maker of the Claude family of chatbots, said on Thursday that it had raised $65bn from private investors after a fundraising round led by Altimeter Capital, Greenoaks, Dragoneer and Sequoia Capital.Funding and Leadership PositionThe announcement catapults Anthropic, led by CEO and cofounder Dario Amodei, ahead of ChatGPT maker OpenAI in value, which attracted an $852bn valuation in its last fundraising round in March. "This funding will help us serve the historic demand we are experiencing, stay at the research frontier, and bring Claude to more of the places where work happens," Anthropic's Chief Financial Officer Krishna Rao said in a statement.Market Recognition and AdoptionAltimeter Capital CEO Brad Gerstner hailed the adoption of Claude among the "world's most demanding organisations" as evidence of Anthropic's command in the field. "This momentum positions Anthropic to lead the next phase of AI innovation and capture the enormous opportunity ahead," Gerstner said.Rapid Growth and Market PositionFounded in 2021 by former OpenAI researchers, Anthropic has rapidly emerged as one of the leading players in Silicon Valley's scramble to dominate AI. Anthropic's Claude, first launched in 2023, is among the most popular AI models worldwide. In March, the San Francisco-based company said that the chatbot was receiving more than 1 million new sign-ups each day.Challenges and Recent DevelopmentsWhile achieving stellar success in rapid time, Anthropic has also faced challenges – in particular, a high-profile dispute with US President Donald Trump's administration, which has labelled the firm a "supply chain risk" over its refusal to allow unrestricted access to its tools for military purposes. Anthropic unveiled its latest iteration of Claude, Opus 4.8, in a separate announcement on Thursday, calling it a "modest but tangible improvement" on its predecessor.Future Outlook and Market DynamicsAnthropic, OpenAI and Elon Musk's rocket company SpaceX are all expected to go public in the near future in what are expected to be among the biggest initial public offerings in history. Jay R Ritter, an emeritus professor at the University of Florida who specialises in IPOs, said Anthropic has generated a lot of market excitement due to its widespread use by companies for software coding. "This is a big market where apparently Anthropic has the best product," Ritter told Al Jazeera.Valuation Trends and Market Analysis"The increase in valuation in a short period of time is unprecedented for a startup, although publicly traded tech companies such as SK Hynix, Nvidia, and Alphabet have seen even bigger increases, although not as much in percentage terms," Ritter said, referring to the South Korean and US chip giants, and Google's parent company. While it remains to be seen whether the massive investments pouring into AI are creating a bubble, Ritter said, the handful of successful firms that are likely to emerge in the field could see enormous profits.Industry Consolidation and Future Prospects"Nobody wants to use the eighth best product, so these companies are either one of the handful of successful firms, or they will have a zero market share," he said. "The tech industry is different than the restaurant industry, where there are not large economies of scale, and where competition limits the profit margins."

The Pavlovian Paradox: Mosquitoes Learn to Associate DEET with FoodFor decades, the efficacy of DEET (N,N-diethyl-meta-toluamide) has been attributed solely to its chemical properties, which are believed to either repel insects or block their ability to detect humans. However, a new study led by Professor Claudio Lazzari from the University of Tours suggests a more complex behavioral interaction. The research indicates that mosquitoes can learn to associate the scent of DEET with the presence of a blood meal, effectively turning a repellent into a lure through a process similar to Pavlovian conditioning.Experimental Evidence: From Repellent to LureThe study, published in the Journal of Experimental Biology, involved trapping mosquitoes and presenting them with warm blood that was just out of reach. The insects were simultaneously exposed to DEET. The results demonstrated a significant shift in behavior:Trained Group: 60% of mosquitoes that fed while exposed to DEET subsequently attempted to bite when exposed to the repellent alone.Control Groups: Significantly lower percentages were observed in untrained insects (17%) and those with prior exposure to DEET alone (13%).In a real-world test, nearly 60% of the trained mosquitoes attempted to bite a researcher's DEET-treated hand, whereas untrained mosquitoes universally targeted the untreated hand.Redefining Insect Control StrategiesThis discovery represents a significant shift in our understanding of how repellents work. It suggests that the reaction to DEET is not merely a chemical aversion but can be modified by experience. Experts, including Dr. Nina Stanczyk of ETH Zürich, emphasize that while the learning ability of mosquitoes is impressive, the implications for public health are nuanced. The study highlights that repellents may function differently depending on the context of the mosquito's previous interactions with humans.Future Outlook for TravelersDespite the alarming findings, experts urge travelers not to abandon DEET. The consensus is that this phenomenon occurs under specific laboratory conditions and is unlikely to happen frequently in the wild due to the variability of repellents encountered during different blood meals. The key takeaway for the future is the importance of consistent application. As noted by the researchers, the risk of association is highest when the repellent starts to wear off, reinforcing the need for regular reapplication to maintain protection.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

In April 2024, a local wildlife ranger recorded a pale horseshoe whip snake gliding through the turquoise waters between Ibiza and the tiny islet of Santa Eulària, providing the first indisputable visual proof that the invasive snake can swim and expand its range across the Balearics.The First Video Confirms Snakes Swimming Between Ibiza and Santa EulàriaThe footage, shot on a minuscule island 450 metres off Ibiza’s east coast, validates long‑standing anecdotal reports from fishermen and tourists. Biologist Oriol Lapiedra of the Centre for Ecological Research and Forestry Applications (Creaf) noted that while snake sightings were common, this was “the first proper evidence” of a snake making the crossing.Captures and Projections Reveal a Rapidly Expanding Snake PopulationMore than 3,500 horseshoe whip snakes were captured on Ibiza in 2025 alone.Since 2016, over 16,000 individuals have been culled.Scientists forecast that the species will occupy 100 % of the island by the end of 2027.On the mainland, snakes rarely exceed 1.8 m in length, but Ibiza specimens have been recorded at over 2 m and weighing 2.5 times as much.Ecological Fallout: Endangered Wall Lizards Face Near‑ExtinctionThe Ibiza wall lizard (Podarcis pityusensis) was upgraded by the IUCN in October 2022 from “near threatened” to “endangered”, reflecting the mounting pressure from the snake. On Santa Eulària, researchers counted 72 lizards in 2016 but only three in 2023. Across the ten islets that once hosted unique lizard populations, many have now lost their native reptiles entirely, erasing thousands of years of isolated evolution.Future Outlook: Management Strategies and the Likelihood of Island‑Wide InfestationRegional authorities, in partnership with Creaf and conservation NGOs, are intensifying capture programmes and exploring “Noah’s ark” captive‑breeding projects to preserve genetic stock. However, the sheer scale of the snake invasion—driven by imported olive trees that provide hidden refuges—means that without sustained effort, the horseshoe whip snake could dominate the Balearic archipelago, reshaping its ecosystems for decades to come.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The Rise of Nigeria's Digital Herbal Marketplace In Abuja, Nigeria, Oke Bola thought a fertility supplement she found online might help her conceive. Instead, within days of taking it, she struggled to breathe. Her experience reflects a growing online trade in unverified herbal remedies promoted across social media platforms. Bola, who is in her early 40s and has never had children, bought the supplement earlier this year and increased the recommended dosage, hoping for quicker results after hearing about it from friends and family. "I recognised the symptoms of asthma; the wheezing sound at night was familiar," she told Al Jazeera. "When I checked online, I realised it could be from the herbal medication." Her experience is not isolated. Across Nigeria, doctors and pharmacists report a surge in social media-driven self-medication, particularly involving unverified herbal products. This trend is worsening health outcomes, delaying treatment, and adding pressure to an already strained healthcare system serving about 230 million people. Nigeria's young, hyperconnected population increasingly uses digital platforms for health information and advice. But that access has also created what Dr Isaac Kolawole and Dr Fidelis describe as an "algorithmic apothecary" – an unregulated online marketplace where influencers and anonymous sellers promote remedies directly to consumers with little or no scientific backing. Health Impacts of Unverified Herbal Remedies Within this ecosystem, herbal remedies, long part of Nigeria's medical and cultural landscape, are increasingly repackaged as miracle cures, sometimes with dangerous consequences. Doctors report more patients arriving at hospitals only when their conditions have significantly worsened, often after prolonged use of unverified treatments. A consultant nephrologist at the University College Hospital in Ibadan, Dr Yemi Raji, said herbal medicine continues to play a role in kidney disease cases in Nigeria. "When you take herbal medication, you are taking both the good and the bad," he said. "Patients often arrive late, when treatment is more difficult and expensive." Dialysis alone can cost between 50,000 and 100,000 naira ($36-72) per session, several times a week. Studies link herbal use to kidney and liver disease cases across Africa, including findings that about 46 percent of liver disease admissions in one Nigerian hospital involved herbs or roots. A 2022 study found that 76.65 percent of participants had used herbal medicine, with more than a third combining herbal and conventional treatments while 82.44 percent did not inform their doctors. The Algorithmic Amplification Effect On a smartphone screen, relief is just a click away: fertility tonics, eye drops promising restored vision, syrups claiming to "flush out" disease. The advertisements are polished, persuasive and constant, woven into TikTok, Facebook, Instagram and X feeds. "The platforms themselves amplify this effect," said Dr Egemba Chinonso Fidelis, a public health advocate known online as Aproko Doctor. "Their algorithms reward engaging content and push it to wider audiences." Even users who try to avoid such content often encounter it repeatedly, shaped by emotional storytelling, music and urgency-driven messaging. A 2025 Nigeria-based study on Jinja Herbal Mixture found it appeared safe for short-term use within tested dosage ranges, but researchers recorded biochemical changes at higher doses, including altered creatinine and sodium levels in test subjects, signs of possible kidney and liver stress. The study called for further research into long-term effects and interactions with conventional medicines. Regulatory Challenges in the Digital Age The National Agency for Food and Drug Administration and Control (NAFDAC) says it is working to track unregistered manufacturers, but enforcement remains difficult, especially online. "With the sheer volume of products online, enforcement has limited reach," said Isaac Kolawole, the southwest zonal director of NAFDAC. Many sellers use fake or incomplete addresses, making them difficult to trace. NAFDAC requires strict registration, testing and approval before herbal products can be sold or advertised, but regulation has not kept pace with online commerce. Fidelis argued that stronger regulation alone is not enough. "If there are no consequences for lying about healthcare online, people will keep doing it," he said. He noted that scammers have even used AI-generated versions of his image to promote fake products. "Real medicine does not promise to cure everything, and it does not rely on countdowns," he added. "Scammers do." Path Forward for Safer Digital Health As Nigeria's digital economy expands, the intersection of technology and healthcare will only grow more complex. Fidelis stressed that access to affordable healthcare must improve, public trust must be rebuilt, and digital platforms must take responsibility for the health content they amplify. Pharmacist Akinade Akinlolu noted that while conditions like diabetes and hypertension can be managed, online claims often suggest cures. "Economic pressure is also pushing people towards cheaper or 'miracle' alternatives," he added. "Without stronger safeguards," Fidelis warned, "the algorithmic apothecary will continue to grow and put more people at risk." The challenge for Nigeria's healthcare system is to harness the power of digital platforms while ensuring they promote evidence-based care rather than potentially harmful alternatives.